MTOR and cancer: E2–The pro-proliferative consequences of PI3K-mTOR signaling activation by GPER1 and the strong response to the presence of GPER1 antagonist therapy during cancer development and progression, as evidenced by in vivo human data (Ferrín et al., 2020; Tian et al., 2023).